Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2448 • ACR Convergence 2025
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Haiting Wang¹, Liling Zhao², Shuang Ye³ and Shaoying Yang², ¹Renji Hospital, Rockville, MD, ²Renji hospital, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
Abstract Number: 2431 • ACR Convergence 2025
Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
Sungwon Ko¹, Young-Eun Kim¹, Soyoon Yoon², Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee³, Bin Yoo¹, Dong Yun Lee⁴ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea, ³Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea, ⁴Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a noninvasive imaging modality widely used to assess inflammatory activity in various autoimmune and hematologic…
Abstract Number: 2411 • ACR Convergence 2025
The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
Luca Mazzoleni¹, Francesca Crisafulli², Md Yuzaiful Md Yusof³, Aamir Aslam⁴, Andrew Barr⁵, Lesley-Anne Bissell⁶, Shouvik Dass⁵, Jack E Arnold⁷, Ed Vital⁸, Franco Franceschini⁹ and Porntip Intapiboon¹⁰, ¹University of Brescia, Brescia, Italy, ²ASST Spedali Civili and University of Brescia, Brescia, Italy, ³University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds teaching hospitals- NHS trust, Leeds, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁷Leeds Institute of Rheumatic & Musculoskeletal Medicine, Leeds, United Kingdom, ⁸University of Leeds, Leeds, England, United Kingdom, ⁹University of Brescia, Brescia, Brescia, Italy, ¹⁰Prince Of Songkla universitiy, Tambon Kohong, Thailand
Background/Purpose: To assess the 2012 SLICC and 2019 EULAR/ACR classification criteria performance as diagnostic criteria in two cohorts of ANA-positive patients clinically suspected of having…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 2201 • ACR Convergence 2025
Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Akhil Sood¹, Leanna Wise², Sadaf Sediqi¹, Alyssa Howren¹, Amanda Moyer¹, Ellie Diamond¹, Yashaar Chaichian³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²LAGMC/Keck Medicine of USC, Los Angeles, ³Stanford University, Stanford, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: The American College of Rheumatology has established guidelines for managing reproductive health in patients with rheumatic diseases. We assessed contraception use and counseling of…
Abstract Number: 1918 • ACR Convergence 2025
Vigorous Physical Activity in Patients with SLE Was Not Associated with Disease Activity or Socioeconomic and Social Factors
Heather Gold¹, Yi Li¹, Isabella Giunta¹, Jill Buyon¹, Peter Izmirly², Mala Masson³, Amit Saxena¹, H Michael Belmont⁴, Chung-E Tseng⁵ and Rebecca Anthopolos¹, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Health, New York, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Flushing, NY
Background/Purpose: Physical activity can mitigate cardiovascular disease and depression risk and improve fatigue, physical function, and quality of life in patients with SLE. To facilitate…
Abstract Number: 1847 • ACR Convergence 2025
Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Sarah McCuaig¹, Julia Rood¹, Em Elliott¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²CHOP, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1817 • ACR Convergence 2025
Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
Heather Cross¹, Hannah Peckham¹, Gary Butler², Elizabeth Rosser³, Elizabeth C Jury¹, George Robinson¹ and Coziana Ciurtin¹, ¹University College London, London, United Kingdom, ²University College London Hospital NHS Trust, London, England, United Kingdom, ³University College London, London, England, United Kingdom
Background/Purpose: Sex determinants may play a role in the immunological sexual dimorphism of childhood-onset systemic lupus erythematosus (cSLE). This study aimed to investigate the impact…
Abstract Number: 1717 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Benny Rashuamán-Conche¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Anubhav Singh⁴, Cristina Reategui-Sokolova⁵, Claudia Elera-Fitzcarrald⁵, Samira Garcia-Hirsh⁶, Cesar Pastor-Asurza⁷, Zoila Rodriguez-Bellido⁸, Risto Perich-Campos⁹, Graciela Alarcón¹⁰ and Manuel Ugarte-Gil¹¹, ¹Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Baptist hospital of southeast Texas, Beaumont, TX, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁸Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁹Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ¹⁰The University of Alabama at Birmingham, Oakland, CA, ¹¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Frailty has been shown to predict damage accrual in patients with SLE, including those from Latin America. However, the impact of frailty on mortality…
Abstract Number: 1634 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus With Incident Heart Failure Requiring Hospitalization
Chun-Yu Lin, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan (Republic of China)
Background/Purpose: Cardiovascular complications are increasingly recognized as a significant cause of late mortality in patients with systemic lupus erythematosus (SLE). Although coronary heart disease risk…
Abstract Number: 1538 • ACR Convergence 2025
Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Minoru Hasegawa¹, Jun Kinoshita², Shigeki Otsubo³, Kana Yamada³ and Ehsanollah Esfandiari⁴, ¹Division of Medicine, University of Fukui, Yoshida-gun, Fukui, Japan, ²Kyowa Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Kyowa Kirin Co., Ltd., Tokyo, Japan, ⁴Kyowa kirin International plc, London, United Kingdom
Background/Purpose: Plasmacytoid dendritic cells (pDCs) are known to be the main source of type 1 interferon (IFN), which is the cause of various autoimmune diseases.…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1496 • ACR Convergence 2025
Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Manikandan Gopal¹, Ashish Jacob Mathew² and john mathew³, ¹christian medical college, Vellore, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) with acute myelitis or optic neuritis is rare and causes significant morbidity. Data on these conditions remain limited. This study…
Abstract Number: 1479 • ACR Convergence 2025
Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Chen Chao¹, Garrett Thomas², Catherine O’Brien², Davina Chen³, Sundus Mian⁴, Tamar Rubinstein⁵, Noa Schwartz⁴ and Bryan Freilich², ¹Rheumatology Division, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, ²Department of Psychiatry, Montefiore Medical Center, Bronx, NY, ³Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New Rochelle, NY, ⁴Division of Rheumatology, Department of Medicine, Montefiore Medical Center, New York, NY, ⁵Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: Up to 80% of Systemic Lupus Erythematosus (SLE) patients experience cognitive dysfunction (CD), which is a top distressing symptom affecting their quality of life.(1)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].